| 发明名称 |
Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis |
| 摘要 |
<p>This invention relates to the use of aryl ureas in the manufacture of a medicament for treating or preventing diseases characterized by abnormal angiogenesis or hyperpermeability processes which are mediated by the VEGF induced signal transduction pathway.</p> |
| 申请公布号 |
SI1478358(T1) |
申请公布日期 |
2013.09.30 |
| 申请号 |
SI20030032285T |
申请日期 |
2003.02.11 |
| 申请人 |
BAYER HEALTHCARE LLC |
发明人 |
DUMAS JACQUES;SCOTT WILLIAM J.;ELTING JAMES;HATOUM-MAKDAD HOLIA |
| 分类号 |
C07D213/81;A61K31/17;A61K31/40;A61K31/421;A61K31/426;A61K31/44;A61K31/4436;A61K31/445;A61K31/454;A61K31/4709;A61K31/4725;A61K31/496;A61K31/497;A61K31/5377;A61K31/54;A61P1/04;A61P1/16;A61P1/18;A61P3/10;A61P7/00;A61P7/02;A61P9/00;A61P9/04;A61P9/10;A61P11/00;A61P17/00;A61P17/02;A61P17/06;A61P19/02;A61P19/08;A61P19/10;A61P25/00;A61P25/28;A61P27/02;A61P29/00;A61P31/04;A61P31/06;A61P31/16;A61P31/18;A61P31/20;A61P33/06;A61P35/00;A61P35/02;A61P35/04;A61P37/02;A61P37/06;A61P37/08;A61P39/02;A61P43/00 |
主分类号 |
C07D213/81 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
|
| 地址 |
|
